Breast Cancer Index’s Post

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

Learn about all the misconceptions regarding extended endocrine therapy to treat HR+, early -stage breast cancer. And let’s not have women suffer with unnecessary side effects. Find out more with the link below:

There are several misconceptions regarding extended endocrine therapy to treat HR+, early-stage breast cancer. Learn the data. Find out more about the Breast Cancer Index test: https://bit.ly/3BC0U1i Hologic, Inc. #BreastCancerAwarenessMonth #Hologic #BustTheMyth #breastcancerindex

Newly published results reveal a significant proportion of early-stage HR+ breast cancer survivors may be over- or undertreated without the Breast Cancer Index test. Learn more at https://bit.ly/43bfab2.

October is #BreastCancerAwareness Month! There are several methods available for breast cancer screening, with digital mammography being the most common. However, not all patients benefit equally from early detection through mammograms, and some may require more advanced screening. It is essential for patients to be aware of factors that could influence their choice of screening exams to make informed decisions before undergoing breast cancer screening. Learn more! https://lnkd.in/eF4MgYTs #BreastCancer #AdvancedScreening #CancerScreening

November’s awareness topic is Lung Cancer! Read one of our latest articles where we look at research that found that Loqtorzi, in addition to chemotherapy, may improve survival in small cell lung cancer. During the phase 3 EXTENTORCH study, researchers discovered that the addition of Loqtorzi to chemotherapy as a first-line treatment for patients with ES-SCLC significantly improved progression-free survival (PFS) and overall survival (OS), while maintaining a tolerable safety profile. Read now: https://ow.ly/8n3g50Uh15S #LungCancer #AwarenessTopic #CUREEducation

Please join CellCarta and RareCyte, Inc. for this insightful webinar on Her2 expression, next week (May 29th). #PrecisionMedicine #CirculatingTumorCells #LiquidBiopsy #CellCarta #RareCyte

Attempts to inhibit CDK2 with conventional modalities have led to substantial toxicities, likely due to inadequate target specificity. CSO Sharon Townson comments on why we believe our CDK2-targeted molecular glue degraders could represent a new combination option for the treatment of HR-positive/HER2-negative breast cancer: https://bit.ly/4f8gpvL